Tags

Type your tag names separated by a space and hit enter

The convalescent sera option for containing COVID-19.
J Clin Invest. 2020 04 01; 130(4):1545-1548.JCI

Links

Publisher Full Text
ncbi.nlm.nih.gov
doi.org
PMC Free PDF
Aggregator Full Text

Authors+Show Affiliations

Casadevall A
Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
Pirofski LA
Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.

MeSH

Antibodies, ViralBetacoronavirusBlood DonorsCOVID-19Coronavirus InfectionsHistory, 20th CenturyHistory, 21st CenturyHumansImmunization, PassivePandemicsPneumonia, ViralRisk AssessmentSARS-CoV-2

Pub Type(s)

Historical Article
Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

32167489

Clinical Trial Links

Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19
SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)
Safety in Convalescent Plasma Transfusion to COVID-19
Stress and Anxiety Levels of Mothers Lying in the Baby Newborn Intensive Care Unit
Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma
Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia
Convalescent Plasma as Adjunct Therapy for COVID-19
Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19
Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma
Hyperimmune Plasma in Patients With COVID-19 Severe Infection
Efficacy and Safety of COVID-19 Convalescent Plasma
Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults

Citation

Casadevall, Arturo, and Liise-Anne Pirofski. "The Convalescent Sera Option for Containing COVID-19." The Journal of Clinical Investigation, vol. 130, no. 4, 2020, pp. 1545-1548.
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545-1548.
Casadevall, A., & Pirofski, L. A. (2020). The convalescent sera option for containing COVID-19. The Journal of Clinical Investigation, 130(4), 1545-1548. https://doi.org/10.1172/JCI138003
Casadevall A, Pirofski LA. The Convalescent Sera Option for Containing COVID-19. J Clin Invest. 2020 04 1;130(4):1545-1548. PubMed PMID: 32167489.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The convalescent sera option for containing COVID-19. AU - Casadevall,Arturo, AU - Pirofski,Liise-Anne, PY - 2020/3/14/pubmed PY - 2020/4/9/medline PY - 2020/3/14/entrez KW - COVID-19 SP - 1545 EP - 1548 JF - The Journal of clinical investigation JO - J Clin Invest VL - 130 IS - 4 SN - 1558-8238 UR - https://www.unboundmedicine.com/medline/citation/32167489/full_citation L2 - https://doi.org/10.1172/JCI138003 DB - PRIME DP - Unbound Medicine ER -